ABSI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Absci Corp (ABSI) is not a good buy for a beginner investor with a long-term strategy at this time. The stock exhibits bearish technical indicators, weak financial performance, and lacks positive catalysts or strong institutional support. Additionally, analysts have downgraded the stock, and there are no recent signals from Intellectia Proprietary Trading Signals to suggest a strong buying opportunity.
The stock shows bearish technical indicators: the MACD is negative and expanding downward, RSI is neutral but leaning toward oversold, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock closed below its pivot support level (S1: 2.484), indicating further downside risk. The short-term trend suggests a likelihood of continued negative price movement.
NULL. There are no recent news updates, no significant insider buying, and no congressional trading activity to suggest a positive catalyst for the stock.
Hedge funds are selling heavily, with a 1029.38% increase in selling activity last quarter. Analysts have downgraded the stock, citing increased risk and reduced visibility of near-term execution. The company's financial performance is weak, with a significant YoY revenue drop (-77.78%) and negative EPS growth (-16.67%).
In Q3 2025, Absci Corp reported a sharp revenue decline (-77.78% YoY) and a net income loss of -$28.7M, though this was a slight improvement (+4.77% YoY). EPS dropped to -0.2 (-16.67% YoY), reflecting ongoing financial struggles. Gross margin remained flat at 100%, but this is overshadowed by the company's inability to generate positive earnings or revenue growth.
Recent analyst activity is negative. Morgan Stanley downgraded the stock to Equal Weight from Overweight and reduced the price target to $4.32 from $5.80, citing increased risk and reduced execution visibility. While H.C. Wainwright raised its price target to $8, this was based on speculative potential from the ABS-201 program, which is still in preclinical stages and carries significant uncertainty.
